Webinar
The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results, Practical Considerations for Personalized Cancer Care
On-demand
For patients with advanced non-small cell lung cancer (NSCLC), tissue samples are typically small biopsies. These samples undergo standard of care evaluation for >10 biomarkers to identify targeted, personalized therapies. If only single-gene tests are ordered, it is unlikely all biomarkers will be successfully tested. Furthermore, the patient may not be able to get a second biopsy for comprehensive testing. Ordering single-gene tests before comprehensive profiling creates longer wait times for results, which can be problematic for selecting optimal treatment.
Join Drs. Kyle C. Strickland and Rebecca A. Previs from Labcorp Oncology’s Medical Affairs team for this webinar to hear about tissue stewardship from a pathologist and oncologist’s perspectives. We will review our latest data from advanced NSCLC which demonstrate that single-gene testing, if performed prior to comprehensive genomic profiling, doubles comprehensive genomic profiling failures due to tissue insufficiency and DNA extraction failures. We will share best practices to optimize tissue utilization and ensure patients with advanced NSCLC receive all recommended biomarker testing.
Learning Objectives:
- Describe the various tissue testing methodologies available for evaluation of biomarkers for patients with advanced NSCLC.
- Compare biomarker testing paradigms with single gene testing and comprehensive genomic profiling to describe benefits and pitfalls of each strategy.
- Integrate best practices for tissue stewardship to optimize biomarker testing in advanced NSCLC.
Kyle Strickland, MD, PhD
Dr. Strickland is board-certified in Anatomic Pathology and Cytopathology. He graduated from the NIH-funded Medical Scientist Training Program at the Medical University of South Carolina. He performed his Ph.D. research on the enzymatic pathways of folate biochemistry, and he completed residency in Anatomic Pathology, followed by sub-specialty fellowship training in Cytopathology and Gynecologic Pathology, at Brigham and Women’s Hospital, Harvard Medical School. Prior to joining our team, Dr. Strickland was Associate Professor of Pathology at Duke University, where he has retained an adjunct faculty position. Dr. Strickland has authored/co-authored over 42 manuscripts in peer-reviewed journals, including the New England Journal of Medicine and JAMA Oncology. His research interests include the molecular pathogenesis of disease, with a particular focus on women’s oncology issues, such as ovarian, uterine, and thyroid cancers.
Rebecca Previs, MD, MS
Dr. Rebecca Previs is a board-certified gynecologic oncologist with expertise in women’s health, precision medicine and early phase clinical trials. Prior to joining Labcorp as the Director of Medical Affairs, she was an Assistant Professor of Gynecologic Oncology at Duke Cancer Institute and Duke University School of Medicine. As the principal investigator of an externally-funded translational laboratory, her work focused on pre-clinical development of novel cancer therapies and tumor immune microenvironment. Dr. Previs obtained her medical degree from the University of Virginia where she first realized her passion for women’s health and caring for patients with cancer. She completed a residency in Obstetrics & Gynecology at Duke University Medical Center followed by a fellowship in gynecologic oncology at The University of Texas MD Anderson Cancer Center. During training, she completed a Master Biomedical Sciences from the University of Texas Graduate School of Biomedical Sciences. Upon completion of training, Dr. Previs joined the Division of Gynecologic Oncology at Duke University, where she operated on patients with newly diagnosed or suspected gynecologic cancers. Her clinical practice focused on enrolling patients with recurrent cancer on early phase and immuno-oncology clinical trials. Becca maintains an adjunct faculty appointment at Duke within the Department of Obstetrics & Gynecology, Division of Gynecologic Oncology in Durham, North Carolina. Dr. Previs continues to prioritize her research and works collaboratively with experts in diverse fields including epidemiology, cancer biology, biomedical engineering, pathology, and immunology to address complex questions in the cancer care continuum. She has served on national clinical trial committees and continues to prioritize mentoring the next-generation of oncologists and scientists.